Preclinical Research
Initiating Rodent Toxicology Studies in 4 to 6 Weeks
Altasciences can initiate rodent toxicology studies in 4 to 6 weeks. As soon as your contract is signed, our experienced team of toxicologists will work closely with you to develop and employ strategies to help move your molecule through the drug development process as quickly as possible, by proactively identifying potential challenges and planning accordingly.
Selecting the right CRO for your studies is critical to the success of your research.
Make the right choice, contact us today.
You may also be interested in the following:
- The Altascientist: Planning your Preclinical Assessment
- The Altascientist: Safety Pharmacology Studies ― a Review
- Insert: Bioanalysis of Small Molecules
- Video: Your Road to Proactive Drug Development with Altasciences
- Webpage: Tell Us Once™
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.
Prioritizing the Compassionate Care of Research Animals
The 3Rs of Animal Research
The 3Rs philosophy is the guiding principle for the Animal Welfare Program at Altasciences.
Altasciences’ Commitment to the 3Rs
In this on-demand podcast, Dr. Christina Cruzen, Attending Veterinarian and Chief Animal Welfare Officer, discusses how Altasciences’ commitment to the 3Rs remains a priority and how it pushes us to continuously advance our animal welfare program.
Here are some examples of recent advancements made to the program:
- Partnered with North American 3Rs Collaborative
- Increased the role of the animal behaviorist to help guide specific study needs
- Established a more robust technical review process by involving a new cross-functional committee
- Further refined procedure cages to better fit animal needs
Listen to this podcast to learn more about how Altasciences’ prioritizes animal welfare to ensure the wellbeing of the research animals in our care.
Questions? Speak to an expert.
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.
You may also be interested in the following:
IND Planning Resources to Get You There Faster
We are ideally positioned to support an efficient, rapid, IND submission to the FDA — for a review of the IND requirements, consult our Preclinical Assessment Planning Guide. Your submission needs to contain comprehensive information in three critical areas:
- Animal pharmacology and toxicology studies
- Manufacturing for producing the drug substance and the drug product
- Detailed protocols for proposed early clinical studies, including clinical investigators, necessary documentation and reviews, all within IND regulations
Altasciences’ Proactive Drug Development platform seamlessly integrates all of these key services, preclinical, manufacturing and early phase clinical, within an integrated partnership.
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept.
You may also be interested in the following:
- Video: Preclinical Services
- The Altascientist: Safety Pharmacology Studies – a Review
- Fact Sheets:
Optimization of a Method for Radio-Telemetry Device Implantation
|
|
The methods used to surgically implant telemetry units to measure cardiovascular function and body temperature in nonhuman primates can impact the quality of the study information obtained. In a recent case study, Altasciences compared the quality of data capture of the standard intra-abdominal implant method versus a less invasive subcutaneous implant method. |
|
Snuggle Wrap-based Restraint Method of Continuous Infusion in Juvenile Nonhuman Primates
Historical Control Database of Cynomolgus Macaque Spermatozoa
Assessment of Subcutaneous Radio-Telepathy Device Implantation in Cynomolgus Monkeys
Nonclinical Safety Assessment for Small Molecules
|
|
Nonclinical safety evaluation generally includes a characterization of toxic effects with respect to target organs, dose dependence, relationship to exposure and, when appropriate, potential reversibility. Nonclinical safety studies, although usually limited at the beginning of clinical development, should be adequate to characterize potential adverse effects that might occur under the conditions of the clinical trial to be supported.
|
|
Video — A Seamless CRO Experience
 |
|
At Altasciences, our integrated, full-service solutions from lead candidate selection to clinical proof of concept are all customizable to your specific needs. Watch as Ingrid Holmes, Vice President, Global Clinical Operations, discusses how we help sponsors bring better drugs to market, faster. |
 |
|
Contact our experts to learn more about our integrated drug development solutions. |